相关实验视频

Updated: May 30, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

在CLL中BTKi诱导的心血管毒性:风险减轻和管理策略

Sofija Kozarac¹, Vojin Vukovic², Michael Fradley³

¹Clinic of Hematology, University Clinical Centre of Serbia, Serbia.

|January 30, 2025

概括

针对慢性淋巴细胞白血病 (CLL) 的布鲁顿氨酸激酶抑制剂 (BTKis) 可能导致心血管不良影响. 本综述研究了BTKi的心脏毒性,重点关注管理策略和血液学见解,以改善患者的治疗结果.

科学领域:

血液学血液学血液学
心脏病学心脏病学
在瘤学瘤学.

背景情况:

针对性治疗,如布鲁顿氨酸激酶抑制剂 (BTKis) 和BCL-2抑制剂是慢性淋巴细胞白血病 (CLL) 的标准.
比特基因与不良事件 (AE) 相关,包括疲劳,伤,感染和心血管并发症.
虽然大多数AE是轻微的,但严重的 (3-4级) 事件可能需要改变治疗.

研究的目的:

在CLL患者中审查BTKi治疗对心血管的影响.
概述BTKi诱导的心血管毒性的实用,多学科的管理策略.
突出血液学对心脏毒性的见解,补充心脏学观点.

主要方法:

分析与ibrutinib和较新的BTKis (acalabrutinib,zanubrutinib,pirtobrutinib) 相关的心血管影响.
专注于特定的心血管风险:心房动,高血压,心律失常,心力衰竭,出血和缺血事件.
对血液学生物标志物和心脏毒性机制的新兴证据的综合.

主要成果:

常见的BTKiAE包括疲劳,伤,感染和心血管问题.
与BTKis观察到的心血管毒性包括心房动,高血压,心力衰竭和缺血事件.
心脏毒性背后的血液学因素越来越被认可.

结论:

心血管毒性是BTKi治疗CLL的一个重要问题.
综合血液学和心脏学的多学科管理对于患者护理至关重要.
对血液学生物标志物和机制的进一步研究可以改善预防和治疗策略.

关键词:

心房动是一种心房动.流血出血流血出血布鲁顿氨酸激酶抑制剂布鲁顿氨酸激酶抑制剂心脏有毒性 - 心脏有毒性慢性淋巴细胞白血病慢性淋巴细胞白血病心脏衰竭是因为心脏衰竭.在高血压的高血压.

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...